Abstract
The consensus statement provided by the workgroup is a valuablesteptowardstimulatingnewresearchinnegative symptoms. It has been very clear for many years that ‘‘negative symptoms’’ play a critical role in producing the severe social and vocational disability experienced by many patients with schizophrenia. At the same time, advancesinassessment,treatment,andtheunderstanding of neurobiologic mechanisms have been slow at best. One example is the striking paucity of large-scale clinical trials that focus on patients selected on the basis of severe and persistent negative symptoms. Despite an enormous number of industry-sponsored trials involving secondgeneration antipsychotics, most of the data on response of ‘‘negative symptoms’’ comes from relatively shortterm trials that focus on patients selected on the basis of positive symptoms (or, for longer-term trials, on the basis of clinical ‘‘stability’’).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
